CONMED Corporation Reports 3.1% Net Sales Increase in Q2 2025

CONMED Corporation reported its financial results for the second quarter of 2025, revealing a net sales increase of 3.1% to $342.3 million compared to $332.1 million in the same period of 2024. For the first half of 2025, net sales reached $663.6 million, up from $644.4 million year-over-year. The company's gross profit for the second quarter was $188.3 million, yielding a gross margin of 55.0%, a slight decrease from 55.3% in the prior year. Net income for the quarter was $21.4 million, or $0.69 per diluted share, down from $30.0 million, or $0.96 per diluted share, in the same quarter last year.

The financial performance reflects a notable shift in operational costs, with selling and administrative expenses rising to $136.0 million in Q2 2025, compared to $122.5 million in Q2 2024. This increase was attributed to higher compensation costs, including $12.2 million related to advisory services provided by the former CEO, and consulting fees for operational optimization. Additionally, the company incurred $5.1 million in costs associated with supply chain improvements, which contributed to the decline in gross profit margins.

In terms of product performance, CONMED's orthopedic surgery segment saw a modest sales increase of 0.9% in Q2 2025, driven by growth in specific product lines such as foot and ankle offerings. The general surgery segment experienced a more significant increase of 4.7%, primarily due to strong sales of the AirSeal® and Buffalo Filter® products. International sales accounted for approximately 44% of total net sales, consistent with the previous year.

On the operational front, CONMED's total assets increased to $2.33 billion as of June 30, 2025, up from $2.31 billion at the end of 2024. The company reported a cash and cash equivalents balance of $33.9 million, an increase from $24.5 million at the end of the previous year. The company’s long-term debt decreased to $881.1 million, down from $905.1 million, reflecting ongoing efforts to manage its capital structure effectively.

Looking ahead, CONMED anticipates continued challenges related to inflation and supply chain disruptions, which may impact its operational results. The company is actively working to mitigate these challenges through strategic initiatives, including engaging a consulting firm to enhance supply chain efficiency. Management remains optimistic about the long-term growth potential of its product lines and is committed to navigating the current economic landscape while maintaining operational stability.